Saturday, April 05, 2014 2:47:36 PM
To better understand this industry one needs to understand the difference between the traditional pharmacy and the compounding pharmacy. In a traditional pharmacy, the pharmacist is handed an Rx from a patient for one drug, usually written for a certain number of pills to be taken once, twice, or three times a day. The patient will pay their copay and the remaining cost of the Rx is charged back to the payer (managed care company) who then reimburses the pharmacy based on negotiated payments schedules. In terms of compound pharmacy, the main difference is the Rx is not for one drug, but for a combination of drugs usually formulated as a cream or gel for topical application. For example, I learned one Rx used to treat pain consists of seven different drugs. As you could imagine, formulating this Rx into a gel or cream is labor intensive, adding the cost of the various medications along with a profit margin, the Rx price could be as much as $3000. The cost of a compounding pharmacy Rx to the patient can vary anywhere between $30 & $50 depending on the co-pay card they have. The remaining cost of the Rx is charged back the payer (managed care) who today is reimbursing the pharmacy in the range of 50%, 75%, and yes even up to 100%. To put that in terms of revenues, one compound pharmacy Rx could generate as much as $1500 to $3000 to the pharmacy. More and more physicians and surgeons are beginning to appreciate the therapeutic benefit of the compounding pharmacy. I believe the potential of this market place is right now in it’s infancy.
I learned from a friend who is a compound pharmacist that pharmacy he works for generates $2M, and growing, each month. Based on a recent PR from Mr. Schneiderman, SCRC is not at that level right now (reported March revenues $494K), but I am sure he is doing everything he can to grow the business. Can you imagine a penny stock company generating revenues of $24M in one year? And that doesn’t even take into consider the potential revenues for RapiMeds in Hong Kong and as we learned earlier Canada, as well as the other not mentioned SCRC revenue streams. So one might ask, why am I excited about SCRC? It’s easy, the business model developed my Mr. Schneiderman, from my own perspective, is destined for success. I won’t even suggest what a P/S will be in the next several months, but my best guess is it will be a lot higher than the .12 range we are at right now.
The value of this IHub is that one can read positive and not so positive posts concerning SCRC. As a result, I highly recommend any new investor to conduct their own DD before taking the next step to invest. I’ll end my post as I always do, GO SCRC!!!
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM